Spondyloarthritis

Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.

Guselkumab represents the first FDA approved medication for active psoriatic arthritis that selectively inhibits interleukin-23.

The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.

The approval is based on the phase 3 PREVENT trial, presented at the European E-Congress of Rheumatology 2020 (EULAR 2020) virtual meeting.

Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.

Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.

Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.

Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.

Study drug also recently showed promise in treating psoriatic arthritis.

The safety profile is consistent with previous studies of the ixekizumab.

Remission and LDA rates generally increased over time in patients with psoriatic arthritis receiving tofacitinib.

The late-breaking data reveal the safety and efficacy of upadacitinib versus placebo and adalimumab.

The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.

In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.

Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.

In both DISCOVER trials, investigators find guselkumab effective against active psoriatic arthritis domains.

The sBLA indication is the fifth for the IL17A inhibitor, which showed reduction of inflammatory signs and symptoms in treated patients at 52 weeks.

A new analysis of data from Northwestern Medicine found some chronic inflammatory diseases were associated with a 7-fold increase in risk of heart failure.

Doses of secukinumab are clinically safe and beneficial for long-term treatment of psoriatic arthritis.

Rheumatology patients are more susceptible to infections, making self-quarantining extremely important for this population.

Patients with psoriatic arthritis are not at an increased risk of cancer, however.

Findings of a phase 3 clinical trial show that patients who take a 15 mg or 30 mg dose achieved higher ACR20, ACR50, and ACR70 scores than those who had a placebo.

Biologics, JAK inhibitors, and opioid alternatives all served major payoffs in the field in the 2010s.

How therapies are advancing treat-to-target strategies, while the field faces a physician shortage issue.

Philip Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, discusses the current state of treatments for psoriatic arthritis.

Elaine Husni, MD, discusses the results of a trial she led examining quality of life changes in psoriatic arthritis patients receiving golimumab over a 1-year period.

Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.

Philip Mease, MD, Director of Rheumatology Research at the Swedish Rheumatology Research Group, discusses why he believes some rheumatologists are skeptical of JAK inhibitors and where they fit in current treatment algorithms.